How did SABS's Q2 2024 EPS forecast compare to past trends?

SAB Biotherapeutics (SABS) is forecasted to report an EPS of -$1.13 for Q2 2024, which is worse than the -$0.79 reported in Q2 2023. This indicates a potential decline in the company's earnings, suggesting a negative outlook for the period. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |SABS|SABS.O|SAB Biotherapeutics|2021 Q1||0.05|186| |SABS|SABS.O|SAB Biotherapeutics|2021 Q2||-0.11|186| |SABS|SABS.O|SAB Biotherapeutics|2021 Q3||-0.16|186| |SABS|SABS.O|SAB Biotherapeutics|2022 Q1|-60|0.02|186| |SABS|SABS.O|SAB Biotherapeutics|2022 Q2|0|-0.11|186| |SABS|SABS.O|SAB Biotherapeutics|2022 Q3|0|-0.16|186| |SABS|SABS.O|SAB Biotherapeutics|2023 Q1|-7400|-1.46|186| |SABS|SABS.O|SAB Biotherapeutics|2023 Q2|-1136.3636363636363|-1.36|186| |SABS|SABS.O|SAB Biotherapeutics|2023 Q3|-506.2499999999999|-0.97|186| |SABS|SABS.O|SAB Biotherapeutics|2024 Q1|63.013698630136986|-0.54|186|